Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 3/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723685 | 0.83 | PRMT6 (0.37) | PRMT6IDH1IDH2SCN9ANPC1 | |
| SCHEMBL6182022 | 0.79 | PRMT6 (0.37) | PRMT6IDH1IDH2NPC1MAPT | |
| SCHEMBL6176672 | 0.77 | L3MBTL1 (0.37) | PRMT6IDH1IDH2SCN9APDE10A | |
| SCHEMBL6178955 | 0.77 | PRMT6 (0.34) | PRMT6IDH1IDH2SCN9A | |
| SCHEMBL6176976 | 0.77 | PRMT6 (0.34) | PRMT6IDH1IDH2SCN9APDE10A | |
| SCHEMBL6178748 | 0.74 | KDM4E (0.38) | PRMT6IDH1SCN9ANPC1 | |
| SCHEMBL6180318 | 0.69 | PRMT6 (0.46) | PRMT6IDH1IDH2PDE10ANPC1 | |
| SCHEMBL8128656 | 0.67 | F10 (0.43) | — | |
| SCHEMBL17949434 | 0.65 | MAPT (0.42) | PRMT6IDH1IDH2NPC1MAPT | |
| SCHEMBL5547613 | 0.65 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427725-B1 | PYRAZOLYL-SUBSTITUTED THIENYLOXYPYRIDINES | BASF AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-20040235667-A1 | Pyrazolyl-substituted thienyloxypyridines | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1427725-A1 | PYRAZOLYL-SUBSTITUTED THIENYLOXYPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022843-A1 | PYRAZOLYL-SUBSTITUTED THIENYLOXYPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235667-A1 | Pyrazolyl-substituted thienyloxypyridines | HDHD5, CBR3, KCNH3 | PRMT6 449/4885IDH1 447/4885IDH2 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.